Transient Cyclic Structured Oligonucleotide Designs for Therapeutic Applications

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Drug Discovery

Background:

• Oligonucleotide therapeutics have evolved significantly, with early efforts focusing on nuclease stability and target affinity, leading to gapmer designs and chemical modifications.
• Established antisense, splice-modulating, and siRNA therapies, now comprising over 25 approved drugs, have advanced the field.
• Recent understanding reveals that oligonucleotides interact with cellular proteins, influencing delivery and innate immune responses.

Purpose of the Study:

• To optimize oligonucleotide drug-like properties by integrating historical chemical advancements with current knowledge of protein interactions.
• To introduce novel cyclic structured oligonucleotide designs that enhance therapeutic efficacy and specificity.

Main Methods:

• Development of cyclic oligonucleotide structures where 3' and 5' ends are temporarily linked through Watson-Crick base pairing.
• Evaluation of these cyclic designs for nuclease resistance during delivery and intracellular release mechanisms.
• Comparative analysis of cyclic designs against traditional gapmer antisense therapeutics.

Main Results:

• Cyclic oligonucleotide structures demonstrate enhanced protection against nucleases during delivery and cell entry.
• These designs facilitate effective release of the oligonucleotide drug into the intracellular environment.
• Significant improvements in potency and specificity were observed compared to gapmer antisense approaches.

Conclusions:

• Cyclic oligonucleotide designs represent a promising advancement in RNA therapeutics, offering improved drug-like properties.
• The transient cyclic structure effectively balances stability for delivery with functional release.
• These designs show broad applicability across diverse RNA therapeutic modalities and mechanisms of action.